IBM unveiled five studies related to Watson's performance in the oncology space at the American Society of Clinical Oncology Annual Meeting in Chicago.
Researchers in multiple countries contributed to the studies. Watson's oncology services are now live or are being implemented at healthcare organizations across the globe, including facilities in Australia, Bangladesh, Brazil, China, India, Mexico, Slovakia, South Korea, Spain, Taiwan, Thailand and the U.S.
Here are the five research findings.
1. Watson for Clinical Trial Matching reduced the time it takes to screen patients for clinical trial eligibility by 78 percent, according to a feasibility study by Rogers, Ark.-based Highlands Oncology Group and Novartis.
2. Watson for Oncology agreed with recommendations from a tumor board in the majority of lung cancer (96 percent), colon cancer (81 percent) and rectal cancer (93 percent) cases, researchers at Bangalore, India-based Manipal Comprehensive Cancer Centre found.
3. Watson for Oncology agreed with oncologists' recommendations for multiple cancer types 83 percent of the time, according to a study at Bangkok, Thailand-based Bumrungrad International Hospital.
4. Watson for Oncology agreed with recommendations from a Incheon, South Korea-based Gachon University Gil Medical Centre tumor board in 73 percent of high-risk colon cancer cases, researchers at the medical center found.
5. Oncologists in Mexico found Watson for Oncology useful for clinics that lack subspecialist expertise, according to a qualitative study out of the Instituto Nacional de Ciencias Médicas y Nutrición and Instituto Nacional de Cancerología in Mexico City.